Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2012
06/28/2012WO2012083493A1 Medicinal composition
06/28/2012WO2012083440A1 A process for the preparation of lapatinib and its ditosylate salt
06/28/2012WO2012083435A1 Selective glycosidase inhibitors and uses thereof
06/28/2012WO2012083414A1 Use of marihuana and compounds therein for treating obesity
06/28/2012WO2012083408A1 Anti-malaria pharmaceutical compositions containing kaurenic diterpene derivatives
06/28/2012WO2012083397A1 Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
06/28/2012WO2012083341A1 Composition for the treatment of skin conditions
06/28/2012WO2012061767A3 Defensin-like molecules as novel antimicrobial agents
06/28/2012WO2012061630A3 Composition and method for treating skin conditions
06/28/2012WO2012061390A3 Therapeutic compositions and methods
06/28/2012WO2012061289A9 Methods for treatment of brain injury utilizing biologics
06/28/2012WO2012061259A3 Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
06/28/2012WO2012060793A3 Process for the preparation of cefdinir formulations
06/28/2012WO2012060789A3 Production method for cefdinir formulations
06/28/2012WO2012060594A3 Anti-inflammatory composition containing a thiourea compound and a pharmaceutically acceptable salt thereof as an active ingredient
06/28/2012WO2012060590A3 Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
06/28/2012WO2012059090A4 Etacrynic acid for use in the treatment of food sensitivity disorders
06/28/2012WO2012058957A3 Polysaccharide extracts of epimedium, fractions thereof and uses thereof in vaccine adjuvants
06/28/2012WO2012053785A3 Sustained-release pellets containing tacrolimus as an active ingredient
06/28/2012WO2012051204A3 Antimicrobial formulations that aid in wound healing
06/28/2012WO2012049222A3 Novel omega-3 and omega-6 fatty acid compositions and uses thereof
06/28/2012WO2012048259A3 Substituted pyridazine carboxamide compounds
06/28/2012WO2012048258A3 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
06/28/2012WO2012047703A3 Cyclopropyl-spiro-piperidines useful as sodium channel blockers
06/28/2012WO2012045072A3 Sugar-based dispersion
06/28/2012WO2012044562A3 Pyrazolopyrimidine pde10 inhibitors
06/28/2012WO2012040082A3 Antidiabetic solid pharmaceutical compositions
06/28/2012WO2012038988A3 Electrolyte fortifying composition for recharge, a hydrating supplement, and process for preparing the same
06/28/2012WO2012037547A3 Methods and compositions for inhibiting autophagy for the treatment of fibrosis
06/28/2012WO2012037410A3 Estrogen receptor modulators and uses thereof
06/28/2012WO2012036529A3 (s)-n,n-dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine derivatives, pharmaceutical compositions containing the derivatives and manufacturing methods thereof
06/28/2012WO2012036433A3 Treatment of neurodegenerative diseases by targeting mirna
06/28/2012WO2012035559A3 Sustained release pharmaceutical compositions comprising pregabalin
06/28/2012WO2012031137A3 Vesicular stomatitis viruses
06/28/2012WO2012030170A3 Novel compound acting as a cannabinoid receptor-1 inhibitor
06/28/2012WO2012030160A3 Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
06/28/2012WO2012024519A4 Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
06/28/2012WO2012022468A3 Benzoquinone derivatives as modulators of mitchondrial function
06/28/2012WO2012022467A3 Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
06/28/2012WO2012013331A3 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
06/28/2012WO2012008764A9 Composition for inducing multiple nuclear division of cells
06/28/2012WO2012007584A3 Composition for the treatment of superficial lesions
06/28/2012WO2011159491A3 Controlled release levetiracetam formulations
06/28/2012WO2011156786A8 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
06/28/2012WO2011156481A3 Formulations including amiodarone and salts thereof and methods of their manufacture and use
06/28/2012WO2011154725A3 Compositions comprising buprenorphine
06/28/2012WO2011141108A3 Dosage forms for cineole
06/28/2012WO2011135464A3 N-(aminoacyl)-amino compound
06/28/2012WO2010015703A3 6 - o - substituted 15 -membered 8a- and 9a - lactams
06/28/2012US20120167240 Compositions and Methods for Modulating PGC-1Alpha to Treat Neurological Diseases and Disorders
06/28/2012US20120165956 Urological medical devices
06/28/2012US20120165795 Therapeutic agent reservoir delivery system
06/28/2012US20120165787 Compositions and methods for treating joints
06/28/2012US20120165782 pharmaceutical composition of an iontophoresis
06/28/2012US20120165522 Camptothecin derivatives
06/28/2012US20120165412 Use of Resveratrol or Another Hydroxylated Stilbene For Preserving Cognitive Functioning
06/28/2012US20120165411 Method for Treating Pancreatitis
06/28/2012US20120165410 Production of encapsulated nanoparticles at high volume fractions
06/28/2012US20120165409 Wrinkle-improving agent
06/28/2012US20120165408 Oral composition for alleviating rough skin
06/28/2012US20120165407 Strategy for on-site in situ generation of oxidizing compounds and application of the oxidizing compound for microbial control
06/28/2012US20120165406 Bis-trifluoromethyl honokiol analogs and their use in treating cancers
06/28/2012US20120165405 Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases
06/28/2012US20120165404 Treatment of neurodegeneration and neuroinflammation
06/28/2012US20120165403 Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor
06/28/2012US20120165402 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
06/28/2012US20120165401 Aptamer for chymase, and use thereof
06/28/2012US20120165400 Gene repair involving in vivo excision of targeting dna
06/28/2012US20120165399 Snornai-small nucleolar rna degradation by rna interference in trypanosomatids
06/28/2012US20120165398 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
06/28/2012US20120165397 Chemical modification of short small hairpin rnas for inhibition of gene expression
06/28/2012US20120165396 Modulation of exportin 5 expression
06/28/2012US20120165395 Bruton's Tyrosine Kinase As Anti-Cancer Drug Target
06/28/2012US20120165394 Spinal muscular atrophy (sma) treatment via targeting of smn2 splice site inhibitory sequences
06/28/2012US20120165393 Peptide-Based In Vivo siRNA Delivery System
06/28/2012US20120165392 Identification of Micro-RNAS Involved in Post-Myocardial Infarction Remodeling and Heart Failure
06/28/2012US20120165391 Use of inhibitors of zdhhc2 activity for modulation of adipogenesis
06/28/2012US20120165390 Compositions and Methods for Therapy and Diagnosis of Cancer
06/28/2012US20120165389 Antisense oligonucleotides that target a cryptic splice site in ush1c as a therapeutic for usher syndrome
06/28/2012US20120165388 Fatty acid binding proteins as drug targets for endocannabinoids
06/28/2012US20120165387 General composition framework for ligand-controlled RNA regulatory systems
06/28/2012US20120165386 Stable oral pharmaceutial composition of atorvastatin
06/28/2012US20120165384 Inhibition of histone acetyltransferases by ctk7a and methods thereof
06/28/2012US20120165383 Inflammatory eye disease
06/28/2012US20120165382 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
06/28/2012US20120165381 Dual-acting imidazole antihypertensive agents
06/28/2012US20120165380 Methods of treating alpha adrenergic mediated conditions
06/28/2012US20120165379 Allantoin-containing skin cream
06/28/2012US20120165378 Thiophene-carboxamides useful as inhibitors of protein kinases
06/28/2012US20120165377 Agent for reducing visceral fat weight
06/28/2012US20120165375 Urea Glucokinase Activators
06/28/2012US20120165373 Method of Treating Skin with microRNA Modulators
06/28/2012US20120165372 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
06/28/2012US20120165371 Spiro substituted compounds as angiogenesis inhibitors
06/28/2012US20120165370 Quinoline derivatives as anti-cancer agents
06/28/2012US20120165369 3-SUBSTITUTED QUINOLINIUM AND 7H-INDOLO[2,3-c]QUINOLINIUM SALTS AS NEW ANTIINFECTIVES
06/28/2012US20120165368 Pyrazolopyridine kinase inhibitors
06/28/2012US20120165367 Azaindazoles useful as inhibitors of kinases
06/28/2012US20120165366 Compounds and uses thereof
06/28/2012US20120165365 Compositions and Methods for Treating Cancer
1 ... 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 ... 7860